Adverse Events Summary
Ryeqo was generally well tolerated in clinical trials1,2
*Placebo for 24 weeks and Ryeqo for 80 weeks.
Bone Mineral Density (BMD)
BMD was preserved with Ryeqo over 104 weeks*3
*The Ryeqo arm includes pooled results from studies on uterine fibroids (LIBERTY 1, LIBERTY 2, LIBERTY 3, and the randomised withdrawal study) and studies on endometriosis
(SPIRIT 1, SPIRIT 2 and SPIRIT 3). BMD was recorded at the lumbar spine.3
Abbreviations: BL, baseline; BMD, bone mineral density; LS, least squares.
References
- Giudice LC et al. Lancet. 2022;399:2267–2279.
- Becker CM et al. Hum Reprod. 2024;39(3):526–537.
- Ryeqo Approved Product Information. January 2024.